Statins decrease perioperative cardiac complications in patients undergoing noncardiac vascular surgery - The statins for risk reduction in surgery (StaRRS) Study

被引:197
作者
O'Neil-Callahan, K
Katsimaglis, G
Tepper, MR
Ryan, J
Mosby, C
Ioannidis, JPA
Danias, PG
机构
[1] Beth Israel Deaconess Med Ctr, Div Cardiovasc, Boston, MA 02215 USA
[2] Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USA
[3] Harvard Univ, Sch Med, Boston, MA USA
[4] Hygeia Hosp, Cardiol Clin 2, Athens, Greece
[5] Naval Hosp, Athens, Greece
[6] Tufts Univ, Sch Med, New England Med Ctr, Inst Clin Res & Hlth Policy Studies, Boston, MA 02111 USA
[7] Univ Ioannina, Sch Med, Dept Hyg & Epidemiol, GR-45110 Ioannina, Greece
关键词
D O I
10.1016/j.jacc.2004.10.048
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVES We sought to assess whether statins may decrease cardiac complications in patients undergoing noncardiac vascular surgery. BACKGROUND Cardiovascular complications account for considerable morbidity in patients undergoing noncardiac surgery. Statins decrease cardiac morbidity and mortality in patients with coronary disease, and the beneficial treatment effect is seen early, before any measurable increase in coronary artery diameter. METHODS A retrospective study recorded patient characteristics, past medical history, and admission medications on all patients undergoing carotid endarterectomy, aortic surgery, or lower extremity revascularization over a two-year period (January 1999 to December 2000) at a tertiary referral center. Recorded perioperative complication outcomes included death, myocardial infarction, ischemia, congestive heart failure, and ventricular tachyarrhythmias occurring during the index hospitalization. Univariate and multivariate logistic regressions identified predictors of perioperative cardiac complications and medications that might confer a protective effect. RESULTS Complications occurred in 157 of 1,163 eligible hospitalizations and were significantly fewer in patients receiving statins (9.9%) than in those not receiving statins (16.5%, p = 0.001). The difference was mostly accounted by myocardial ischemia and congestive heart failure. After adjusting for other significant predictors of perioperative complications (age, gender, type of surgery, emergent surgery, left ventricular dysfunction, and diabetes mellitus), statins still conferred a highly significant protective effect (odds ratio 0.52, p = 0.001). The protective effect was similar across diverse patient subgroups and persisted after accounting for the likelihood of patients to have hypercholesterolemia by considering their propensity to use statins. CONCLUSIONS Use of statins was highly protective against perioperative cardiac complications in patients undergoing vascular surgery in this retrospective study. (C) 2005 by the American College of Cardiology Foundation.
引用
收藏
页码:336 / 342
页数:7
相关论文
共 41 条
[1]   Effect of statin therapy on C-reactive protein levels - The Pravastatin Inflammation/CRP Evaluation (PRINCE): A randomized trial and cohort study [J].
Albert, MA ;
Danielson, E ;
Rifai, N ;
Ridker, PM .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 286 (01) :64-70
[2]   IN-HOSPITAL AND LONG-TERM MORTALITY IN MALE VETERANS FOLLOWING NONCARDIAC SURGERY [J].
BROWNER, WS ;
LI, J ;
MANGANO, DT .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1992, 268 (02) :228-232
[3]  
Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3
[4]   Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques - Implications for plaque stabilization [J].
Crisby, M ;
Nordin-Fredriksson, G ;
Shah, PK ;
Yano, J ;
Zhu, J ;
Nilsson, J .
CIRCULATION, 2001, 103 (07) :926-933
[5]   Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels - Results of AFCAPS/TexCAPS [J].
Downs, JR ;
Clearfield, M ;
Weis, S ;
Whitney, E ;
Shapiro, DR ;
Beere, PA ;
Langendorfer, A ;
Stein, EA ;
Kruyer, W ;
Gotto, AM .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 279 (20) :1615-1622
[6]  
Fox KM, 2003, LANCET, V362, P782
[7]   EFFECT OF LOVASTATIN ON EARLY CAROTID ATHEROSCLEROSIS AND CARDIOVASCULAR EVENTS [J].
FURBERG, CD ;
ADAMS, HP ;
APPLEGATE, WB ;
BYINGTON, RP ;
ESPELAND, MA ;
HARTWELL, T ;
HUNNINGHAKE, DB ;
LEFKOWITZ, DS ;
PROBSTFIELD, J ;
RILEY, WA ;
YOUNG, B .
CIRCULATION, 1994, 90 (04) :1679-1687
[8]   Fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction [J].
Hayashidani, S ;
Tsutsui, H ;
Shiomi, T ;
Suematsu, N ;
Kinugawa, S ;
Ide, T ;
Wen, J ;
Takeshita, A .
CIRCULATION, 2002, 105 (07) :868-873
[9]   Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells [J].
Hernández-Perera, O ;
Pérez-Sala, D ;
Navarro-Antolín, J ;
Sánchez-Pascuala, R ;
Hernández, G ;
Díaz, C ;
Lamas, S .
JOURNAL OF CLINICAL INVESTIGATION, 1998, 101 (12) :2711-2719
[10]  
HOSMER DW, 1989, APPLIED LOGISTICAL R